Want to see SE:SUBGEN full AI Analyst Report?
AegirBio AB (SUBGEN) Financial Statements
AegirBio AB Financial Overview
AegirBio AB's market cap is currently $72.42M. The company's EPS TTM is $-0.11; its P/E ratio is -0.29; AegirBio AB has not announced its next earnings date. See an overview of income statement, balance sheet, and cash flow financials.
| Mar 26 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 204.39M | $ 203.76M | $ 92.00K | $ 1.71M | $ 13.28M |
| Gross Profit | $ 75.16M | $ -14.27M | $ 44.00K | $ -23.71M | $ 5.51M |
| Operating Income | $ -129.21M | $ -36.55M | $ -56.16M | $ -91.48M | $ -83.76M |
| EBITDA | $ -104.63M | $ -27.02M | $ -34.67M | $ -351.78M | $ -74.20M |
| Net Income | $ -88.88M | $ -49.63M | $ -59.70M | $ -362.83M | $ -92.33M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 18.74M | $ 283.00K | $ 12.14M | $ 14.59M | $ 34.03M |
| Total Assets | $ 617.77M | $ 32.61M | $ 53.10M | $ 66.87M | $ 404.37M |
| Total Debt | $ 102.41M | $ 45.48M | $ 32.72M | $ 7.58M | $ 9.83M |
| Net Debt | $ 83.67M | $ 45.20M | $ 20.58M | $ -7.43M | $ -24.20M |
| Total Liabilities | $ 200.62M | $ 71.25M | $ 54.55M | $ 27.04M | $ 33.95M |
| Stockholders' Equity | $ 418.65M | $ -38.65M | $ -1.45M | $ 39.83M | $ 370.42M |
| Cash Flow | |||||
| Free Cash Flow | $ -20.59M | $ -12.58M | $ -47.52M | $ -49.06M | $ -109.37M |
| Operating Cash Flow | $ -12.56M | $ -12.57M | $ -41.94M | $ -49.00M | $ -108.22M |
| Investing Cash Flow | $ -66.47M | $ -15.55M | $ -5.54M | $ -65.00K | $ 1.60M |
| Financing Cash Flow | $ 89.26M | $ 16.24M | $ 45.05M | $ 29.26M | $ 130.25M |
Currency in SEK